Shanghai Apeiron Biotechnology Co. Ltd. has reported selenium-containing heterocyclic compounds acting as DNA polymerase theta (POLθ, POLQ) inhibitors potentially useful for the treatment of cancer.
Recombination Therapeutics LLC and Thomas Jefferson University have synthesized DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has identified thiadiazolyl derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Hangzhou Synrx Therapeutics Technology Co. Ltd. has divulged DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Breakpoint Therapeutics GmbH has nominated its first preclinical DNA damage response development candidate, BTX-011, for the treatment of solid tumors. IND-enabling activities have already commenced.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has described heterocyclic derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
